Anatomical specificity in the modulation of activity-regulated genes after acute or chronic lurasidone treatment

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 50, Issue , 2014, Pages 94-101

  Luoni, Alessia ^a   Rocha, Fabio F ^a   Riva, Marco A ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Arc; Lurasidone; Neuroplasticity; Npas4; Zif268

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; DOPAMINE 2 RECEPTOR; LURASIDONE; NEUROTRANSMITTER RECEPTOR; ACTIVITY REGULATED CYTOSKELETAL-ASSOCIATED PROTEIN; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; CYTOSKELETON PROTEIN; EARLY GROWTH RESPONSE FACTOR 1; EGR1 PROTEIN, RAT; ISOINDOLE DERIVATIVE; NERVE PROTEIN; NEUROLEPTIC AGENT; NPAS4 PROTEIN, RAT; THIAZOLE DERIVATIVE;

ACUTE DRUG ADMINISTRATION; ADULT; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARC GENE; ARTICLE; BRAIN REGION; CELL ACTIVATION; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; CORPUS STRIATUM; DOSE RESPONSE; DRUG EFFECT; DRUG MEGADOSE; FUNCTIONAL ANATOMY; GENE; GENE ACTIVITY; GENE EXPRESSION REGULATION; HIPPOCAMPUS; LOW DRUG DOSE; MALE; NERVE CELL PLASTICITY; NEUROMODULATION; NONHUMAN; NPAS4 GENE; PREFRONTAL CORTEX; RAT; ZIF268 GENE; ANIMAL; BIOSYNTHESIS; DRUG ADMINISTRATION; DRUG EFFECTS; METABOLISM;

ANIMALS; ANTIPSYCHOTIC AGENTS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; BRAIN-DERIVED NEUROTROPHIC FACTOR; CORPUS STRIATUM; CYTOSKELETAL PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EARLY GROWTH RESPONSE PROTEIN 1; HIPPOCAMPUS; ISOINDOLES; MALE; NERVE TISSUE PROTEINS; NEURONAL PLASTICITY; PREFRONTAL CORTEX; RATS; THIAZOLES;

EID: 84891605532     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2013.12.008     Document Type: Article

References (47)

1. An J.J., Gharami K., Liao G.Y., Woo N.H., Lau A.G., Vanevski F., et al. Distinct role of long 3' UTR BDNF mRNA in spine morphology and synaptic plasticity in hippocampal neurons. Cell 2008, 134:175-187.
2. Bonaventure P., Kelly L., Aluisio L., Shelton J., Lord B., Galici R., et al. Selective blockade of 5-hydroxytryptamine (5-HT)7 receptors enhances 5-HT transmission, antidepressant-like behavior, and rapid eye movement sleep suppression induced by citalopram in rodents. J Pharmacol Exp Ther 2007, 321:690-698.
3. Bonaventure P., Aluisio L., Shoblock J., Boggs J.D., Fraser I.C., Lord B., et al. Pharmacological blockade of serotonin 5-HT(7) receptor reverses working memory deficits in rats by normalizing cortical glutamate neurotransmission. PLoS One 2011, 6:e20210.
4. Bramham C.R., Worley P.F., Moore M.J., Guzowski J.F. The immediate early gene arc/arg3.1: regulation, mechanisms, and function. J Neurosci 2008, 28:11760-11767.
5. Bruins Slot L.A., Lestienne F., Grevoz-Barret C., Newman-Tancredi A., Cussac D. F15063, a potential antipsychotic with dopamine D(2)/D(3) receptor antagonist and 5-HT(1A) receptor agonist properties: influence on immediate-early gene expression in rat prefrontal cortex and striatum. Eur J Pharmacol 2009, 620:27-35.
6. Calabrese F., Molteni R., Maj P.F., Cattaneo A., Gennarelli M., Racagni G., et al. Chronic duloxetine treatment induces specific changes in the expression of BDNF transcripts and in the subcellular localization of the neurotrophin protein. Neuropsychopharmacology 2007, 32:2351-2359.
7. Calabrese F., Molteni R., Riva M.A. Antistress properties of antidepressant drugs and their clinical implications. Pharmacol Ther 2011, 132:39-56.
8. Calabrese F., Luoni A., Guidotti G., Racagni G., Fumagalli F., Riva M.A. Modulation of neuronal plasticity following chronic concomitant administration of the novel antipsychotic lurasidone with the mood stabilizer valproic acid. Psychopharmacology (Berl) 2013, 226:101-112.
9. Cates L.N., Roberts A.J., Huitron-Resendiz S., Hedlund P.B. Effects of lurasidone in behavioral models of depression. Role of the 5-HT receptor subtype. Neuropharmacology 2013, 70C:211-217.
10. Chourbaji S., Brandwein C., Vogt M.A., Dormann C., Hellweg R., Gass P. Nature vs. nurture: can enrichment rescue the behavioural phenotype of BDNF heterozygous mice?. Behav Brain Res 2008, 192:254-258.
11. Chourbaji S., Brandwein C., Gass P. Altering BDNF expression by genetics and/or environment: impact for emotional and depression-like behaviour in laboratory mice. Neurosci Biobehav Rev 2011, 35:599-611.
12. Chourbaji S., Hortnagl H., Molteni R., Riva M.A., Gass P., Hellweg R. The impact of environmental enrichment on sex-specific neurochemical circuitries-effects on brain-derived neurotrophic factor and the serotonergic system. Neuroscience 2012, 220:267-276.
13. Covington H.E., Vialou V., Nestler E.J. From synapse to nucleus: novel targets for treating depression. Neuropharmacology 2010, 58:683-693.
14. Delille H.K., Becker J.M., Burkhardt S., Bleher B., Terstappen G.C., Schmidt M., et al. Heterocomplex formation of 5-HT2A-mGlu2 and its relevance for cellular signaling cascades. Neuropharmacology 2012, 62:2184-2191.
15. Enomoto T., Ishibashi T., Tokuda K., Ishiyama T., Toma S., Ito A. Lurasidone reverses MK-801-induced impairment of learning and memory in the Morris water maze and radial-arm maze tests in rats. Behav Brain Res 2008, 186:197-207.
16. Fumagalli F., Bedogni F., Frasca A., Di Pasquale L., Racagni G., Riva M.A. Corticostriatal up-regulation of activity-regulated cytoskeletal-associated protein expression after repeated exposure to cocaine. Mol Pharmacol 2006, 70:1726-1734.
17. Fumagalli F., Frasca A., Racagni G., Riva M.A. Antipsychotic drugs modulate Arc expression in the rat brain. Eur Neuropsychopharmacol 2009, 19:109-115.
18. Fumagalli F., Calabrese F., Luoni A., Bolis F., Racagni G., Riva M.A. Modulation of BDNF expression by repeated treatment with the novel antipsychotic lurasidone under basal condition and in response to acute stress. Int J Neuropsychopharmacol 2012, 15:235-246.
19. Fumagalli F., Calabrese F., Luoni A., Shahid M., Racagni G., Riva M.A. The AMPA receptor potentiator Org 26576 modulates stress-induced transcription of BDNF isoforms in rat hippocampus. Pharmacol Res 2012, 65:176-181.
20. Gasbarri A., Cifariello A., Pompili A., Meneses A. Effect of 5-HT(7) antagonist SB-269970 in the modulation of working and reference memory in the rat. Behav Brain Res 2008, 195:164-170.
21. Guzowski J.F., Lyford G.L., Stevenson G.D., Houston F.P., McGaugh J.L., Worley P.F., et al. Inhibition of activity-dependent arc protein expression in the rat hippocampus impairs the maintenance of long-term potentiation and the consolidation of long-term memory. J Neurosci 2000, 20:3993-4001.
22. Hedlund P.B., Huitron-Resendiz S., Henriksen S.J., Sutcliffe J.G. 5-HT7 receptor inhibition and inactivation induce antidepressantlike behavior and sleep pattern. Biol Psychiatry 2005, 58:831-837.
23. Horiguchi M., Huang M., Meltzer H.Y. The role of 5-hydroxytryptamine 7 receptors in the phencyclidine-induced novel object recognition deficit in rats. J Pharmacol Exp Ther 2011, 338:605-614.
24. Horisawa T., Ishibashi T., Nishikawa H., Enomoto T., Toma S., Ishiyama T., et al. The effects of selective antagonists of serotonin 5-HT7 and 5-HT1A receptors on MK-801-induced impairment of learning and memory in the passive avoidance and Morris water maze tests in rats: mechanistic implications for the beneficial effects of the novel atypical antipsychotic lurasidone. Behav Brain Res 2011, 220:83-90.
25. Ishibashi T., Horisawa T., Tokuda K., Ishiyama T., Ogasa M., Tagashira R., et al. Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. J Pharmacol Exp Ther 2010, 334:171-181.
26. Ishiyama T., Tokuda K., Ishibashi T., Ito A., Toma S., Ohno Y. Lurasidone (SM-13496), a novel atypical antipsychotic drug, reverses MK-801-induced impairment of learning and memory in the rat passive-avoidance test. Eur J Pharmacol 2007, 572:160-170.
27. Jones M.W., Errington M.L., French P.J., Fine A., Bliss T.V., Garel S., et al. A requirement for the immediate early gene Zif268 in the expression of late LTP and long-term memories. Nat Neurosci 2001, 4:289-296.
28. Knapska E., Kaczmarek L. A gene for neuronal plasticity in the mammalian brain: Zif268/Egr-1/NGFI-A/Krox-24/TIS8/ZENK?. Prog Neurobiol 2004, 74:183-211.
29. Lieberman J.A., Bymaster F.P., Meltzer H.Y., Deutch A.Y., Duncan G.E., Marx C.E., et al. Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection. Pharmacol Rev 2008, 60:358-403.
30. Lin Y., Bloodgood B.L., Hauser J.L., Lapan A.D., Koon A.C., Kim T.K., et al. Activity-dependent regulation of inhibitory synapse development by Npas4. Nature 2008, 455:1198-1204.
31. Luoni A., Hulsken S., Cazzaniga G., Racagni G., Homberg J.R., Riva M.A. Behavioural and neuroplastic properties of chronic lurasidone treatment in serotonin transporter knockout rats. Int J Neuropsychopharmacol 2012, 20:1-12.
32. Meltzer H.Y., Cucchiaro J., Silva R., Ogasa M., Phillips D., Xu J., et al. Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study. Am J Psychiatry 2011, 168:957-967.
33. Miyamoto S., Duncan G.E., Marx C.E., Lieberman J.A. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry 2005, 10:79-104.
34. Molteni R., Calabrese F., Mancini M., Racagni G., Riva M.A. Basal and stress-induced modulation of activity-regulated cytoskeletal associated protein (Arc) in the rat brain following duloxetine treatment. Psychopharmacology (Berl) 2008, 201:285-292.
35. Molteni R., Calabrese F., Cattaneo A., Mancini M., Gennarelli M., Racagni G., et al. Acute stress responsiveness of the neurotrophin BDNF in the rat hippocampus is modulated by chronic treatment with the antidepressant duloxetine. Neuropsychopharmacology 2009, 34:1523-1532.
36. Molteni R., Calabrese F., Racagni G., Fumagalli F., Riva M.A. Antipsychotic drug actions on gene modulation and signaling mechanisms. Pharmacol Ther 2009, 124:74-85.
37. Olivier J.D., Van Der Hart M.G., Van Swelm R.P., Dederen P.J., Homberg J.R., Cremers T., et al. A study in male and female 5-HT transporter knockout rats: an animal model for anxiety and depression disorders. Neuroscience 2008, 152:573-584.
38. Park S.W., Phuong V.T., Lee C.H., Lee J.G., Seo M.K., Cho H.Y., et al. Effects of antipsychotic drugs on BDNF, GSK-3beta, and beta-catenin expression in rats subjected to immobilization stress. Neurosci Res 2011, 71:335-340.
39. Paxinos G., Watson C. The rat brain in stereotaxis coordinates 1996, Academic Press, New York.
40. Pei Q., Lewis L., Sprakes M.E., Jones E.J., Grahame-Smith D.G., Zetterstrom T.S. Serotonergic regulation of mRNA expression of Arc, an immediate early gene selectively localized at neuronal dendrites. Neuropharmacology 2000, 39:463-470.
41. Pei Q., Zetterstrom T.S., Sprakes M., Tordera R., Sharp T. Antidepressant drug treatment induces Arc gene expression in the rat brain. Neuroscience 2003, 121:975-982.
42. Roberts A.J., Hedlund P.B. The 5-HT(7) receptor in learning and memory. Hippocampus 2012, 22:762-771.
43. Tarazi F.I., Riva M.A. The preclinical profile of lurasidone: clinical relevance for the treatment of schizophrenia. Expert Opin Drug Discov 2013, 10:10.
44. Tokarski K., Bobula B., Grzegorzewska-Hiczwa M., Kusek M., Hess G. Stress- and antidepressant treatment-induced modifications of 5-HT(7) receptor functions in the rat brain. Pharmacol Rep 2012, 64:1305-1315.
45. Wesolowska A., Tatarczynska E., Nikiforuk A., Chojnacka-Wojcik E. Enhancement of the anti-immobility action of antidepressants by a selective 5-HT7 receptor antagonist in the forced swimming test in mice. Eur J Pharmacol 2007, 555:43-47.
46. Ying S.W., Futter M., Rosenblum K., Webber M.J., Hunt S.P., Bliss T.V., et al. Brain-derived neurotrophic factor induces long-term potentiation in intact adult hippocampus: requirement for ERK activation coupled to CREB and upregulation of Arc synthesis. J Neurosci 2002, 22:1532-1540.
47. Yuen E.Y., Li X., Wei J., Horiguchi M., Meltzer H.Y., Yan Z. The novel antipsychotic drug lurasidone enhances n-methyl-d-aspartate receptor-mediated synaptic responses. Mol Pharmacol 2012, 81:113-119.